Stephan Christgau, Senior Partner
Novo Seeds.
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-03-25 15:37:232019-03-25 15:37:23Company creation and early-stage investing in life sciences: A Novo Seeds perspectiveNomination deadline 11th April 2019
https://www.optimumcomms.com/wp-content/uploads/2022/09/Inkef-In-Vivo-QA.jpg
317
500
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-03-18 16:41:092019-03-18 16:41:09Nominations for The European Mediscience Awards 2019 open nowJohn Cassidy
Investment Associate
Arix Bioscience plc
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-03-18 15:07:332019-03-18 15:07:33Mapping opportunities and challenges in biotech investmentRobert James
Managing Partner
Sixth Element Capital
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-03-05 11:42:362019-03-05 11:42:36Bridging the investment gap between drug discovery and clinical development in oncologyWill this trend continue? Analysis of Biopharma M&A in 2018 (and previous years)
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-02-08 16:51:152019-02-08 16:51:15Pan European M&A at record levels in 2018